WO2002092826A3 - Composition and method for treating cancer using herpes virus - Google Patents
Composition and method for treating cancer using herpes virus Download PDFInfo
- Publication number
- WO2002092826A3 WO2002092826A3 PCT/JP2002/004547 JP0204547W WO02092826A3 WO 2002092826 A3 WO2002092826 A3 WO 2002092826A3 JP 0204547 W JP0204547 W JP 0204547W WO 02092826 A3 WO02092826 A3 WO 02092826A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- present
- herpes virus
- provides
- virus
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/763—Herpes virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16061—Methods of inactivation or attenuation
- C12N2710/16062—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16641—Use of virus, viral particle or viral elements as a vector
- C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16651—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02769559A EP1387694A2 (en) | 2001-05-09 | 2002-05-09 | Composition and method for treating cancer using herpes virus |
AU2002307749A AU2002307749A1 (en) | 2001-05-09 | 2002-05-09 | Composition and method for treating cancer using herpes virus |
JP2002589692A JP4372422B2 (en) | 2001-05-09 | 2002-05-09 | Compositions and methods for cancer treatment using herpes virus |
US10/477,444 US7264814B2 (en) | 2001-05-09 | 2002-05-09 | Composition and method for treating cancer using herpes virus |
US11/827,108 US20080069837A1 (en) | 2001-05-09 | 2007-07-09 | Composition and method for treating cancer using herpes virus |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001-139094 | 2001-05-09 | ||
JP2001139094 | 2001-05-09 | ||
JP2001300931 | 2001-09-28 | ||
JP2001-300931 | 2001-09-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002092826A2 WO2002092826A2 (en) | 2002-11-21 |
WO2002092826A3 true WO2002092826A3 (en) | 2003-09-25 |
Family
ID=26614839
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2002/004547 WO2002092826A2 (en) | 2001-05-09 | 2002-05-09 | Composition and method for treating cancer using herpes virus |
Country Status (7)
Country | Link |
---|---|
US (2) | US7264814B2 (en) |
EP (3) | EP2140879A1 (en) |
JP (2) | JP4372422B2 (en) |
AU (1) | AU2002307749A1 (en) |
ES (1) | ES2539941T3 (en) |
HK (1) | HK1145435A1 (en) |
WO (1) | WO2002092826A2 (en) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPQ425699A0 (en) | 1999-11-25 | 1999-12-23 | University Of Newcastle Research Associates Limited, The | A method of treating a malignancy in a subject and a pharmaceutical composition for use in same |
EP2140879A1 (en) * | 2001-05-09 | 2010-01-06 | M'S Science Corporation | Composition and method for treating cancer using herpes virus |
DE50303607D1 (en) * | 2002-09-09 | 2006-07-06 | Medifact Publishing Gmbh | METHOD FOR THE LOCAL DETECTION OF INFLAMMATORY AND ALLERGY MEDIATORS |
AU2002953436A0 (en) | 2002-12-18 | 2003-01-09 | The University Of Newcastle Research Associates Limited | A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis |
US20080226677A1 (en) | 2004-05-06 | 2008-09-18 | Yasuko Mori | Recombinant virus vector for gene transfer into lymphoid cells |
JPWO2006115170A1 (en) * | 2005-04-21 | 2008-12-18 | 国立大学法人名古屋大学 | HSV1-HF10 virus therapy for head and neck cancer |
US20100008944A1 (en) * | 2005-07-29 | 2010-01-14 | President And Fellows Of Harvard College | Herpes simplex virus mutant and uses therefore |
US8865185B2 (en) | 2006-09-08 | 2014-10-21 | The Trustees Of The University Of Pennsylvania | Methods of use for HSV-1 and HSV-2 vaccines |
CA2663109A1 (en) * | 2006-09-08 | 2008-03-13 | The Trustees Of The University Of Pennsylvania | Hsv-1 and hsv-2 vaccines and methods of use thereof |
US10478490B2 (en) | 2006-12-28 | 2019-11-19 | The Trustees Of The University Of Pennsylvania | Herpes simplex virus combined subunit vaccines and methods of use thereof |
US8057804B2 (en) | 2006-12-28 | 2011-11-15 | The Trustees Of The University Of Pennsylvania | Herpes simplex virus combined subunit vaccines and methods of use thereof |
JP6144448B2 (en) | 2006-12-28 | 2017-06-07 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | Herpes simplex virus complex subunit vaccine and method of use thereof |
US8765444B2 (en) * | 2009-07-15 | 2014-07-01 | The Board Of Trustees Of The University Of Illinois | Compositions and methods using herpes simplex virus |
CN102657861A (en) * | 2010-08-16 | 2012-09-12 | 郑州金森生物科技工程有限公司 | Herpes simplex virus I-type gene recombinant attenuated live vaccine and preparation method thereof |
CN102657862B (en) * | 2010-08-16 | 2015-09-30 | 郑州金森生物科技工程有限公司 | Herpes simplex virus type II gene recombinaton attenuated live vaccine and preparation method thereof |
CN102671193A (en) * | 2010-08-16 | 2012-09-19 | 郑州金森生物科技工程有限公司 | Herpes simplex virus II type gene recombined attenuated live vaccine and preparation method thereof |
WO2013023362A1 (en) * | 2011-08-16 | 2013-02-21 | 深圳市卫武光明生物制品有限公司 | Cytomegalovirus human immunoglobulin for intravenous injection, and preparation method therefor |
CA2794397A1 (en) * | 2011-10-27 | 2013-04-27 | Institut National De La Recherche Scientifique | Modulation of ul24 interactions with protein targets and uses thereof for inhibition of herpesvirus infection |
WO2014164699A1 (en) * | 2013-03-11 | 2014-10-09 | The Regents Of The University Of California | Herpes virus vaccines and treatments |
US9616119B2 (en) | 2014-03-24 | 2017-04-11 | University Of Kansas | Neuroattenuated herpes simplex virus |
PE20180463A1 (en) * | 2015-06-30 | 2018-03-06 | Ceva Sante Animale | DUCK ENTERITIS VIRUS AND USES OF IT |
EP3393490A4 (en) * | 2015-12-15 | 2019-11-20 | Icahn School of Medicine at Mount Sinai | METHODS OF TREATING EXACERBATED INFLAMMATORY RESPONSE WITH TOPOISOMERASE l INHIBITORS |
JP2019512501A (en) * | 2016-03-14 | 2019-05-16 | レッドバイオテック・アーゲーRedbiotec Ag | Means and method for treating HSV |
KR102323872B1 (en) * | 2016-04-22 | 2021-11-08 | 임비라 컴퍼니 리미티드 | CONSTRUCTION OF ONCOLYTIC HERPES SIMPLEX VIRUSES (oHSV) OBLIGATE VECTOR AND CONSTRUCTS FOR CANCER THERAPY |
EP3263129A1 (en) * | 2016-06-29 | 2018-01-03 | Ceva Sante Animale | Duck enteritis virus and the uses thereof |
US20210138009A1 (en) * | 2018-06-08 | 2021-05-13 | The Board Of Trustees Of The University Of Illinois | Recombinant Herpes Simplex Virus for Cancer Immunotherapy |
KR101974169B1 (en) * | 2018-08-10 | 2019-04-30 | 의료법인 성광의료재단 | Recombinant herpes simplex virus and method for manufacturing the same |
CN110904058B (en) * | 2018-09-14 | 2023-03-07 | 中国农业科学院哈尔滨兽医研究所(中国动物卫生与流行病学中心哈尔滨分中心) | Recombinant duck plague virus vaccine and construction method and application thereof |
JP7388777B2 (en) * | 2019-08-16 | 2023-11-29 | イムヴィラ・カンパニー・リミテッド | Pharmaceutical compositions containing oncolytic herpes simplex virus for systemic administration |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998042195A1 (en) * | 1997-03-27 | 1998-10-01 | University Of Cincinnati | Replication-competent herpes simplex viruses |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
GB8918616D0 (en) * | 1989-08-15 | 1989-09-27 | Univ Glasgow | Herpes simplex virus type 1 mutant |
US5728379A (en) | 1994-06-23 | 1998-03-17 | Georgetown University | Tumor- or cell-specific herpes simplex virus replication |
GB9415319D0 (en) * | 1994-07-29 | 1994-09-21 | Medical Res Council | HSV viral vector |
WO1997009999A1 (en) * | 1995-09-11 | 1997-03-20 | Aviron | Methods and compositions for treatment of hsv-2 infections and conditions |
DE69732498T2 (en) * | 1996-07-31 | 2006-04-27 | Ortho-Mcneil Pharmaceutical, Inc. | RECOGNITION OF HUMAN CYTOMEGALOVIRUS GENES THAT REDUCE THE EXPRESSION OF MHC CLASS I HEAVY CHAINS |
GB9816781D0 (en) * | 1998-07-31 | 1998-09-30 | Univ London | Herpes virus vectors for dendritic cells |
AU772471B2 (en) * | 1999-02-05 | 2004-04-29 | Arch Development Corporation | Treatment of tumors with genetically engineered herpes virus |
EP2140879A1 (en) * | 2001-05-09 | 2010-01-06 | M'S Science Corporation | Composition and method for treating cancer using herpes virus |
-
2002
- 2002-05-09 EP EP09075398A patent/EP2140879A1/en not_active Withdrawn
- 2002-05-09 AU AU2002307749A patent/AU2002307749A1/en not_active Abandoned
- 2002-05-09 WO PCT/JP2002/004547 patent/WO2002092826A2/en active Application Filing
- 2002-05-09 JP JP2002589692A patent/JP4372422B2/en not_active Expired - Lifetime
- 2002-05-09 EP EP10000308.6A patent/EP2213300B1/en not_active Expired - Lifetime
- 2002-05-09 EP EP02769559A patent/EP1387694A2/en not_active Withdrawn
- 2002-05-09 ES ES10000308.6T patent/ES2539941T3/en not_active Expired - Lifetime
- 2002-05-09 US US10/477,444 patent/US7264814B2/en not_active Expired - Lifetime
-
2007
- 2007-07-09 US US11/827,108 patent/US20080069837A1/en not_active Abandoned
-
2008
- 2008-06-06 JP JP2008149907A patent/JP2009005696A/en not_active Withdrawn
-
2010
- 2010-12-15 HK HK10111671.1A patent/HK1145435A1/en not_active IP Right Cessation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998042195A1 (en) * | 1997-03-27 | 1998-10-01 | University Of Cincinnati | Replication-competent herpes simplex viruses |
Non-Patent Citations (2)
Title |
---|
PYLES R B ET AL: "EVIDENCE THAT THE HERPES SIMPLEX VIRUS TYPE 1 URACIL DNA GLYCOSYLASE IS REQUIRED FOR EFFICIENT VIRAL REPLICATION AND LATENCY IN THE MURINE NERVOUS SYSTEM", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 68, no. 8, August 1994 (1994-08-01), pages 4963 - 4972, XP002911541, ISSN: 0022-538X * |
See also references of EP1387694A2 * |
Also Published As
Publication number | Publication date |
---|---|
HK1145435A1 (en) | 2011-04-21 |
EP2213300B1 (en) | 2015-03-25 |
JP2004535798A (en) | 2004-12-02 |
EP2140879A1 (en) | 2010-01-06 |
WO2002092826A2 (en) | 2002-11-21 |
JP4372422B2 (en) | 2009-11-25 |
US7264814B2 (en) | 2007-09-04 |
ES2539941T3 (en) | 2015-07-07 |
US20080069837A1 (en) | 2008-03-20 |
EP2213300A1 (en) | 2010-08-04 |
JP2009005696A (en) | 2009-01-15 |
AU2002307749A1 (en) | 2002-11-25 |
US20040228876A1 (en) | 2004-11-18 |
EP1387694A2 (en) | 2004-02-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002092826A3 (en) | Composition and method for treating cancer using herpes virus | |
HK1214298A1 (en) | Recombinant influenza viruses for vaccines and gene therapy | |
WO2004028454A3 (en) | 1, 3, 5-triazines for treatment of viral diseases | |
AU2002233643A1 (en) | Methods of treating diseases in association with decrease in the expression of AOP-1 gene or AOP-1 and remedies for the diseases | |
AU2003278816A1 (en) | ss-L-2'-DEOXYNUCLEOSIDES FOR THE TREATMENT OF RESISTANT HBV STRAINS AND COMBINATION THERAPIES | |
WO2004080398A3 (en) | 1-amino 1h-imidazoquinolines | |
WO2003082200A3 (en) | Potent oncolytic herpes simplex virus for cancer therapy | |
PL352554A1 (en) | Sulfonamide or sulfamide substituted amidazoquinolines | |
WO1999038955A3 (en) | Mutant herpes simplex viruses and uses thereof | |
AU2003225281A1 (en) | Materials and methods for prevention and treatment of rna viral diseases | |
WO2002006513A3 (en) | A method for treating herpes viruses | |
AU2001251613A1 (en) | Novel genes, compositions and methods for the identification, assessment, prevention, and therapy of human cancers | |
AU2001245987A1 (en) | Compositions and methods for gene therapy | |
WO2001079164A3 (en) | N-substituted dithiocarbamates for the treatment of biological disorders | |
MXPA03003741A (en) | Methods and compositions for the treatment of diseases of the eye. | |
AU2074101A (en) | Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer | |
WO2004030631A3 (en) | Anti-cancer and anti-infectious disease compositions and methods for using same | |
AU2003292045A1 (en) | Use of soluble forms of cd83 and nucleic acids encoding them for the treatment or prevention of diseases | |
WO2001091789A3 (en) | Combination of a mutant herpes virus and a chemotherapeutic agent for the treatment of cancer | |
AU2003285946A1 (en) | Identification of antimycobacterial targets and the inhibition thereof as a treatment for infectious diseases | |
AU2001251138A1 (en) | Compositions and methods for tissue specific gene regulation therapy | |
AU2003285482A1 (en) | Methods and means for the treatment of inflammatory disorders involving genotyping of the 5, 10- methylenetetrahydrofolate reductase (mthfr) gene | |
WO2003080800A3 (en) | Prevention and treatment of disease using angiogenesis-and/or tumor antigens | |
GB0115382D0 (en) | Mutant | |
WO2003008595A3 (en) | Novel oligoribonucleotide derivatives for the targeted inhibition of gene expression |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002589692 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10477444 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002769559 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002769559 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |